Are COVID-19 test results masking important issues?

Owen, Brandon; Shepherd, Simon

doi:10.1038/s41432-020-0117-3

Cited by 1 publication

(1 citation statement)

References 4 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The nucleic acid test and antibody detection are widely used in SARS-CoV-2 infection diagnosis, but high false-negative rates have been reported [18] , [19] . In our study, all the double-negative population had increased serum α- l -fucosidase activity.…”

Section: Discussionmentioning

confidence: 99%

Clinical relevance of serum α-l-fucosidase activity in the SARS-CoV-2 infection

Liang

Wang

et al. 2021

Clinica Chimica Acta

View full text Add to dashboard Cite

Background and aims The reduced fucosylation in the spike glycoprotein of SARS-CoV-2 and the IgG antibody has been observed in COVID-19. However, the clinical relevance of α- l -fucosidase, the enzyme for defucosylation has not been discovered. Materials and methods 585 COVID-19 patients were included to analyze the correlations of α- l -fucosidase activity with the nucleic acid test, IgM/IgG, comorbidities, and disease progression. Results Among the COVID-19 patients, 5.75% were double-negative for nucleic acid and antibodies. All of them had increased α- l -fucosidase, while only one had abnormal serum amyloid A (SAA) and C-reactive protein (CRP). The abnormal rate of α- l -fucosidase was 81.82% before the presence of IgM, 100% in the presence of IgM, and 66.2% in the presence of IgG. 73.42% of patients with glucometabolic disorders had increased α- l -fucosidase activity and had the highest mortality of 6.33%. The increased α- l -fucosidase was observed in 55.8% of non-severe cases and 72.9% of severe cases, with an odds ratio of 2.118. The α- l -fucosidase mRNA was irrelevant to its serum activity. Conclusion The change in α- l -fucosidase activity in COVID-19 preceded the IgM and SAA and showed a preferable relation with glucometabolic disorders, which may be conducive to virus invasion or invoke an immune response against SARS-CoV-2.

show abstract

Section: Discussionmentioning

confidence: 99%